Celosia Therapeutics

Brenton Hamdorf, Ph.D., CEO

Oct. 10 | 4:30pm | Rentschler ATMP Ballroom 

Sydney, AU


Celosia Therapeutics is a late discovery/early pre-clinical phase gene therapy company developing treatments for neurodegenerative disease. The initial focus is on the development of a treatment for Amyotrophic Lateral Sclerosis (Motor Neuron Disease). ALS is a terminal motor neuron disease for which there remains no effective treatment. The proposed gene therapy targets pathogenic TDP43 aggregates in the cytoplasm restoring cellular proteostasis through targeted protein degradation, preventing neuronal cell death, and thus disease progression.


By using this website you agree to accept our Privacy Policy and Terms & Conditions